Watch TSHA. Know when insiders buy.
One email the day a filing lands. Free.
TSHA
Taysha Gene Therapies, Inc.
4.74
−0.13 −2.67%
USD · close Oct 1
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
50
WATCH · shorts 50
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.5BP/E —DIV YIELD —FCF YIELD -8.58%REV TTM $5.5M −32.3%NET INCOME −$149.6MNET CASH $417.1M52W 3.83 – 6.98SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | −100.0% | — | −$47.3M | −$46.6M | — | -0.13 | −$40.4M | −$1K | −$40.4M | Aug 11 |
| Q1 2026 · Mar 31 | $0 | −100.0% | — | −$43.5M | −$42.4M | — | -0.12 | −$40.9M | $24K | −$40.9M | May 6 |
| Q4 2025 · Dec 31derived | $5.5M | +171.3% | — | −$28.3M | −$27.9M | — | -0.08 | −$26.7M | $250K | −$27M | Mar 19 |
| Q3 2025 · Sep 30 | $0 | −100.0% | — | −$34M | −$32.7M | — | -0.09 | −$24.2M | $108K | −$24.3M | Nov 4 |
| Q2 2025 · Jun 30 | $2M | +78.6% | — | −$26.8M | −$26.9M | — | -0.09 | −$20.2M | $2K | −$20.2M | Aug 11 |
| Q1 2025 · Mar 31 | $2.3M | −32.5% | — | −$21.4M | −$21.5M | — | -0.08 | −$22M | $378K | −$22.4M | May 6 |
| Q4 2024 · Dec 31derived | $2M | −43.9% | — | −$19.9M | −$18.8M | −139.3% | -0.07 | −$18.3M | −$2K | −$18.3M | Mar 19 |
| Q3 2024 · Sep 30 | $1.8M | −62.3% | — | −$25.9M | −$25.5M | — | -0.10 | −$21.6M | $35K | −$21.6M | Nov 4 |
| Q2 2024 · Jun 30 | $1.1M | — | — | −$21.3M | −$20.9M | — | -0.09 | −$21.5M | $201K | −$21.7M | Aug 12 |
| Q1 2024 · Mar 31 | $3.4M | — | — | −$24.3M | −$24.1M | — | -0.10 | −$19.8M | $140K | −$19.9M | May 15 |
| Q4 2023 · Dec 31derived | $3.6M | — | — | −$16.2M | $47.7M | — | 0.92 | −$16.1M | $17K | −$16.1M | Feb 26 |
| Q3 2023 · Sep 30 | $4.7M | — | — | −$16.3M | −$117.1M | — | -0.93 | −$17.9M | $0 | −$17.9M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $9.8M | — | −$110.5M | −$109M | -1115.3% | -0.34 | −$93.1M | $738K | −$93.8M | — | — |
| FY2024 · to Dec 31 | $8.3M | — | −$91.5M | −$89.3M | -1071.6% | -0.36 | −$81.2M | $374K | −$81.6M | — | — |
| FY2023 · to Dec 31 | $15.5M | — | −$72.4M | −$111.6M | -722.1% | -0.96 | −$73M | $3.9M | −$76.9M | — | — |
| FY2022 · to Dec 31 | $2.5M | — | −$162.4M | −$166M | -6635.3% | -3.78 | −$88.4M | $20.6M | −$109M | — | — |
| FY2021 · to Dec 31 | — | — | −$173.3M | −$174.5M | — | -4.64 | −$117M | $15.3M | −$132.3M | — | — |
| FY2020 · to Dec 31 | — | — | −$43M | −$60M | — | -3.40 | −$30.7M | $82K | −$30.8M | — | — |
Every number comes from Taysha Gene Therapies, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.